Thiogenesis Therapeutics has engaged Brisco Capital Partners to enhance communication with investors and raise awareness of its rare disease drug programs. Brisco will receive a monthly fee and stock options as part of the agreement. Additionally, Thiogenesis plans to increase its equity incentive plan reserve to support future stock-based compensation, pending shareholder and regulatory approval. These moves aim to strengthen investor relations and support the company's growth in developing treatments for rare genetic disorders.
First Tellurium's subsidiary PyroDelta Energy has been featured in Metal Tech News for its tellurium-based thermoelectric generators that convert waste heat from AI data centers into clean electricity. This technology reduces energy consumption and c...
Pratt & Whitney is investing $25 million to expand its manufacturing facility in Niepołomice, Poland, which produces complex components for commercial and military aircraft engines. The expansion, expected to be operational by 2028, will create over ...
Group Eleven Resources Corp. has agreed to settle C$32,250 in outstanding director fees owed to former director Alessandro Bitelli by issuing 38,393 common shares at $0.84 each. This move aims to conserve the company's cash for ongoing and planned op...
Three brokerage firms—E*TRADE, J.P. Morgan Self-Directed Investing, and Charles Schwab—are offering attractive new-account bonuses in 2026. E*TRADE provides up to $1,500 cash for funding new accounts, J.P. Morgan offers up to $1,000 cash for transfer...
The IMF announced that El Salvador's recent Bitcoin gains since June 2025 were funded by private donations, not public money, addressing concerns about government Bitcoin purchases. This was revealed during the combined second and third reviews of El...
